Compare Aurora Cannabis Inc (ACB) vs Veritone Inc (VERI) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Veritone (VERI) trades at $1.36, up 3.82% on the day, but remains under significant pressure with a bearish technical signal and negative profitability. The company reported a net loss of $111.73 million in 2025, with a net income margin of -123.76%, while revenue declined slightly to $90 million in 2026. Multiple class-action lawsuits filed in July 2026 allege securities fraud related to improper revenue accounting, creating substantial legal overhangs.

The outlook is highly speculative; while the consensus price target of $5.25 implies significant upside, the stock faces severe fundamental challenges and legal risks. Investment opportunity hinges on successful business turnaround and resolution of litigation, but current financial performance and negative cash flow from operations present substantial downside risk.